the patient tested positive for theSARS-CoV-2; the patient tested positive for theSARS-CoV-2; This is a literature report for the following literature source(s).  A 35-year-old female patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Cardiovascular disease" (unspecified if ongoing); "hospitalized" (unspecified if ongoing); "palpitations" (unspecified if ongoing); "premature ventricular contractions(PVCs)" (unspecified if ongoing); "presyncope" (unspecified if ongoing). The patient's family history included: "diabetes" (unspecified if ongoing); "high blood pressure" (unspecified if ongoing); "cardiac cirrhosis" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (hospitalization, medically significant, life threatening), COVID-19 (hospitalization, medically significant, life threatening), outcome "unknown" and all described as "the patient tested positive for theSARS-CoV-2". The patient underwent the following laboratory tests and procedures: Alanine aminotransferase: 9 IU/l, notes: indicate that she does not have autoimmune hepatitis; Antibody test: Less than 1, notes: showed the absence of DS anti- body, it can be concluded that the patient does not have SLE; Antibody test (normal high range 10): less than 10; Antibody test (normal high range 25): Less than 25; Anti-cyclic citrullinated peptide antibody (normal high range 20): Less than 16; Antineutrophil cytoplasmic antibody: Negative; Antineutrophil cytoplasmic antibody (normal high range 1.0): Less than 1, notes: Unit: antibody index. no anti bodies detected; Less than 1, notes: Unit: antibody index; Antinuclear antibody: 1:80, notes: Low anti body level; Antinuclear antibody (normal high range 1): Less than 1; Antinuclear antibody (normal high range 1.0): Less than 1; Aspartate aminotransferase: 20 IU/l, notes: indicate that she does not have autoimmune hepatitis; Beta-2 glycoprotein antibody (normal high range 20): Less than 2.0, notes: Antibody not detected; Less than 2.0, notes: Antibody not detected; Less than 2.0, notes: Antibody not detected; Blood alkaline phosphatase: 52 IU/l, notes: indicate that she does not have autoimmune hepatitis; Blood cholesterol (normal high range 200): 192 mg/dl; Blood pressure measurement: decreased; Blood triglycerides (normal high range 150): 65 mg/dl; Cardiolipin antibody (normal high range 20): less than 20, notes: Antibody not detected; Less than 2.0, notes: Antibody not detected; Less than 2.0, notes: Antibody not detected; Complement factor C3 (83-193): 91 mg/dl; Complement factor C4 (15-57): 21 mg/dl; Echocardiogram: showed trace mitral regurgitation, notes: showed trace mitral regurgitation, tricuspid regurgitation, and pericardial effusion; Ejection fraction: 62.3 %; Gene mutation identification test: revealed mutations at 6 potential CVD/diabetes, notes: Exploring 100 genes for CVD and diabetes revealed mutations at 6 potential CVD/diabetes mellitus susceptibility loci APOC1 (rs4420638), CETP (rs3764261), IL4 (rs2243250), AGT(rs5051), and AGT (rs699) for CVD and SLC30A8 (c.973C) for diabetes mellitus suggesting moderate risk for developing CVD and/or diabetes mellitus, but no susceptibility genes for immune system disorders; High density lipoprotein (normal low range 50): 79 mg/dl, notes: increased. 1 month; 65 mg/dl, notes: Over 1 year; Immunology test: Positive, notes: positive for auto immune antibodies; Low density lipoprotein (normal high range 100): 115 mg/dl, notes: high. 1 month; 112 mg/dl, notes: over 1 year; Magnetic resonance imaging heart: Showed border line cardiomegaly, notes: Showed border line cardiomegaly with left ventricle enlargement but no evidence of infarct, fibrosis, or amyloidosis; Non-high-density lipoprotein cholesterol (normal high range 130): 127 mg/dl; SARS-CoV-2 test: Positive; Total cholesterol/HDL ratio (normal high range 5): 3. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: A 35-year-old woman presented for evaluation with complaints of fatigue, chest and joint pain, and dyspnea. The patient had a history of cardiovascular disease (CVD), having been hospitalized for 3 days with palpitations and premature ventricular contractions (PVCs) at 1 year and 10 months before her first Pfizer SARS-CoV-2 vaccination. Symptoms resurfaced 3 weeks after patient's second vaccination and worsened progressively, with multiple hospital admissions that included dual cardiac ablations over a 3-month period. Ibuprofen was prescribed for pericarditis 2 months after the second ablation, and 3 weeks later, the patient tested positive for SARS-CoV-2. The patient took only vitamin D to combat SARS-CoV-2 infection. Shortly after testing positive for SARS-CoV-2, the patient presented again with chest pain when moving or breathing, joint pain, and dermatitis, symptoms that persisted for 6 months.; Sender's Comments: Based on known drug safety profile, there is reasonable possibility of causal association between the events DRUG INEFFECTIVE and COVID-19 and BNT162B2.